Ocular Therapeutix, Inc. (OCUL)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Pravin U. Dugel M.D. | Executive Chairman, President & CEO | 1.49M | -- | 1964 |
| Dr. Jeffrey S. Heier M.D. | Chief Scientific Officer | 676.55k | -- | 1961 |
| Dr. Peter K. Kaiser M.D. | Chief Development Officer | 698.87k | -- | 1967 |
| Mr. Donald Notman Jr. | CFO, COO & Principal Accounting Officer | 679.77k | -- | -- |
| Dr. Peter K. Jarrett Ph.D. | Chief Technical Officer | -- | -- | 1957 |
| Mr. William S. Slattery Jr. | Vice President of Investor Relations | -- | -- | -- |
| Mr. Todd D.C. Anderman J.D. | Chief Legal Officer & Corporate Secretary | -- | -- | 1982 |
| Mr. William H. Ransone II | Vice President of Global Sales & Marketing | -- | -- | -- |
| Mr. Barry Rubenstein M.S. | Chief Human Resources Officer | -- | -- | -- |
| Mr. Steve Meyers | Chief Commercial Officer | -- | -- | -- |
Ocular Therapeutix, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 274
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Corporate Governance
Upcoming Events
August 4, 2025 at 8:00 PM UTC - August 8, 2025 at 8:00 PM UTC
Ocular Therapeutix, Inc. Earnings Date